In November 2005, the FDA approved the use of erlotinib in combination with gemcitabine for treatment of locally advanced, unresectable, or metastatic pancreatic cancer.
Bishii Nofeembar 2005, FDA waxay oggolaatay erlotinib oo ay weheliso gemcitabine si loogu daaweeyo kansarka xannuunka maxalliga ah ee horumarsan, aan la xakamayn karin, ama metastatic.